Journal article
Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer
Abstract
IMPORTANCE: Treatment options for platinum-refractory metastatic urothelial cancer (mUC) are limited, and outcomes remain poor. Nab-paclitaxel is an albumin-bound formulation of paclitaxel showing promising activity and tolerability in a prior single-arm trial.
OBJECTIVES: To evaluate the efficacy and safety of nab-paclitaxel vs paclitaxel in platinum-refractory mUC.
Authors
Sridhar SS; Blais N; Tran B; Reaume MN; North SA; Stockler MR; N. K; Fleshner NE; Liu G; Robinson JW
Journal
JAMA Oncology, Vol. 6, No. 11, pp. 1751–1758
Publisher
American Medical Association (AMA)
Publication Date
November 1, 2020
DOI
10.1001/jamaoncol.2020.3927
ISSN
2374-2437